Home | Welcome to Contract Pharma   
Last Updated Thursday, September 18 2014
Print

Financial Report: Baxter



Published January 24, 2013
Baxter
 
4Q Revenues:
$3.8 billion (+4%)

4Q Earnings: $494 million (+7%)

YTD Revenues: $14.2 billion (+2%)

YTD Earnings: $2.3 billion (+5%)

Comments: BioScience revenues were $1.7 billion in the quarter, up 7%. U.S. sales were $1.6 billion, up 7%, driven by sales growth for Advate, and Gammagard Liquid, as well as other plasma-based therapeutics. International sales were up 2% to $2.2 billion. Medical Products sales were $2.1 billion, up 2%, driven primarily by gains in peritoneal dialysis patients in the U.S., as well as growth in intravenous therapies. Results in the quarter included special after-tax items of $206 million related to costs associated with settlement of certain U.S. pension obligations and business optimization initiatives.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On